X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Eyenovia re-acquired the rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline. MicroPine, an investigational ophthalmic spray of atropine delivered by Optejet device, is being evaluated as a potential treatment for pediatric progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: MicroPine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eyenovia
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Acquisition January 16, 2024
Details:
Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent antidote.
Lead Product(s): Atropine,Pralidoxime Chloride
Therapeutic Area: Pharmacology/Toxicology Product Name: DuoDote
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ASPR
Deal Size: $9.9 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2023
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
NVK002 (atropine) is an investigational, preservative-free, low-dose atropine eye drop, using Vyluma’s proprietary technology to address stability, tolerability, and safety and developed for the treatment of Pediatric Myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
NVK002 (atropine) is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 14, 2022
Details:
The financing will support the Phase III clinical study for NVK002, Vyluma’s first-in-class pharmaceutical treatment for slowing the progression of myopia in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 09, 2022
Details:
The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.
Lead Product(s): Atropine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $45.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2022
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
Under the terms of the agreement, Nevakar will develop and obtain European Medicines Agency (“EMA”) approval for NVK-002, and Théa will launch, distribute, and support the product in Europe, as well as in parts of North Africa.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: $135.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 28, 2021
Details:
The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound, NVK-002, to slow the progression of myopia in children. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Under the terms of the agreement, ZKO will develop and obtain regulatory approval for NVK-002 in the contractual territory, where ZKO will manufacture, launch, distribute, and support the commercialization of the product.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nevakar
Deal Size: $102.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
Details:
Bausch Health has acquired an exclusive license in the U.S and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of nearsightedness, in children ages 3-12.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: MicroPine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: $45.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 12, 2020
Details:
Eyenovia will provide pre-recorded updates on the CHAPERONE (evaluation of low-dose atropine for the reduction of pediatric myopia progression) and the VISION (evaluation of low-dose pilocarpine for improvement in near vision) clinical trials.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: MicroPine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
The agreement aims at developing and commercializing MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: MicroPine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arctic Vision
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2020
Details:
Ocumension's IPO marks a significant milestone in its journey to become China's leading ophthalmology platform. Company intent to use these funds to continue expanding its portfolio with innovative new drug assets.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 10, 2020
Details:
The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovia’s proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: MicroPine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
